The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
 
David Michael Gill
No Relationships to Disclose
 
David D. Stenehjem
No Relationships to Disclose
 
Heather H. Cheng
Research Funding - Astellas Medivation; Inovio Pharmaceuticals; Sanofi
 
Elizabeth Riley Kessler
No Relationships to Disclose
 
Andrew W. Hahn
No Relationships to Disclose
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Consulting or Advisory Role - Keryx (I)
Research Funding - Hydrocephalus Clinical Research Network (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Keryx (I)
 
Anitha Alex
No Relationships to Disclose
 
Shiven B. Patel
No Relationships to Disclose
 
Namita Chittoria
No Relationships to Disclose
 
Przemyslaw Twardowski
No Relationships to Disclose
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)